Editor-in-chief Steven P. Ringel, MD, and Associate Editor Robert G. Holloway, MD, discuss the implications of the study and what to tell patients and their families once REM sleep behavior disorder is diagnosed.

]]>Thu, 11 Jul 2013 14:17:32 GMT-05:00http://journals.lww.com/neurotodayonline/pages/videogallery.aspx?videoId=40&autoPlay=truehttp://journals.lww.com/neurotodayonline/pages/videogallery.aspx?videoId=41&autoPlay=true
Neurology Today Editor-in-chief Steven P. Ringel, MD, and Associate Editor Orly Avitzur, MD, Dr. Pedley outlines his top four agenda items. Watch here as he discusses: the AAN focus on advocacy in Washington, DC Academy strategies for tailoring its services and programs to individual members’ interests; how to increase the AAN profile and outreach to an international audience of neurologists; and why he favors supporting more diversity in AAN leadership positions.]]>Wed, 17 Jul 2013 14:52:58 GMT-05:00http://journals.lww.com/neurotodayonline/pages/videogallery.aspx?videoId=41&autoPlay=truehttp://journals.lww.com/neurotodayonline/pages/videogallery.aspx?videoId=42&autoPlay=true
Fri, 26 Jul 2013 12:41:20 GMT-05:00http://journals.lww.com/neurotodayonline/pages/videogallery.aspx?videoId=42&autoPlay=truehttp://journals.lww.com/neurotodayonline/pages/videogallery.aspx?videoId=43&autoPlay=true
JAMA Internal Medicine, reported that primary care physicians are not consistently consulting with patients in discussions and decisions about common tests, medications, and procedures. Neurology Today Editor-in-chief Steven P. Ringel, MD, and Associate Editor Robert Holloway, MD, discuss the pros/cons of shared decision-making with neurology patients – what’s realistic and what’s not.]]>Fri, 26 Jul 2013 12:47:46 GMT-05:00http://journals.lww.com/neurotodayonline/pages/videogallery.aspx?videoId=43&autoPlay=truehttp://journals.lww.com/neurotodayonline/pages/videogallery.aspx?videoId=44&autoPlay=true
Neurology Today Editor-in-chief Steven P. Ringel, MD, and
Associate Editor Orly Avitzur, MD, former AAN
President Dr. Sigsbee discusses the AAN priorities for policy and advocacy, what the office is doing to highlight the challenges facing neurologists, what is being done about the “Medicaid bump,” and what members can do to support their cause.]]>Thu, 08 Aug 2013 12:38:54 GMT-05:00http://journals.lww.com/neurotodayonline/pages/videogallery.aspx?videoId=44&autoPlay=truehttp://journals.lww.com/neurotodayonline/pages/videogallery.aspx?videoId=45&autoPlay=true
Neurology Today article,
“Why Hospital Prices Vary: What Neurologists Should Know,” the Centers for Medicare and Medicaid Services (CMS) released in May a list of the average 2011 charges for the 100 most common Medicare inpatient services at more than 3,300 hospitals. Among the data, for example, one hospital in Philadelphia charged $234,913 to treat an inpatient suffering intracranial hemorrhage with major complications while another hospital in Pittsburgh charged $9,539. Shortly thereafter, CMS released data on what those hospitals charged for 30 common outpatient services — reflecting similar disparities in charges. In a video interview, Neurology Today Editor-in-Chief Steven P. Ringel, MD, and Associate Editor Robert Holloway, MD, discuss the disparities, why neurologists need to pay attention to the “Choosing Wisely” campaign, and what they can tell their patients about the variable charges — for example, higher charges should not be equated with better outcomes for care.]]>Thu, 08 Aug 2013 13:16:44 GMT-05:00http://journals.lww.com/neurotodayonline/pages/videogallery.aspx?videoId=45&autoPlay=truehttp://journals.lww.com/neurotodayonline/pages/videogallery.aspx?videoId=46&autoPlay=true
Neurology Today Editor-in-chief Steven P. Ringel, MD, and Associate Editor Robert Holloway, MD, discuss why it is imperative for neurologists to participate in efforts to improve the processes associated with delivering care and reduce the related costs. Standardization of care is an important priority, Dr. Ringel says in the video. The good news is that there are tools to help neurologists achieve that and other quality improvements, he added.]]>Thu, 29 Aug 2013 09:33:09 GMT-05:00http://journals.lww.com/neurotodayonline/pages/videogallery.aspx?videoId=46&autoPlay=truehttp://journals.lww.com/neurotodayonline/pages/videogallery.aspx?videoId=47&autoPlay=true
In a July 19 online study in The Lancet, investigators reported that people with epilepsy are overall 11.1 times more likely to die prematurely than unaffected persons, 5.5 times more likely to die from nonvehicle accidents, and 3.7 times more likely to die from suicide. Among persons with epilepsy who die from an external cause, three-quarters of the cases involve a psychiatric diagnosis. In a video interview, Neurology Today Editor-in-chief Steven P. Ringel, MD, and Associate Editor Robert Holloway, MD, discuss the pros and cons of the study methodology data — a review of data from national Swedish registry.

]]>Wed, 25 Sep 2013 14:40:23 GMT-05:00http://journals.lww.com/neurotodayonline/pages/videogallery.aspx?videoId=47&autoPlay=truehttp://journals.lww.com/neurotodayonline/pages/videogallery.aspx?videoId=48&autoPlay=true
What are the caveats of a system that applies transcranial magnetic stimulation to the brain and records high definition EEG responses? In a study reported in the Aug. 14 Science Translational Medicine, the investigators
compressed the spatiotemporal pattern into a single value, ranging from 0-1, and reported, that using that formula, they were able to reliably differentiate levels of consciousness across a wide group of people — from healthy people during wakefulness, sleep, or under different sedatives; to patients in a locked-in state who can’t move on command but who understand everything; to those who have been diagnosed as minimally conscious; to others in a persistent vegetative state. In a video interview, Neurology Today Editor-in-chief Steven P. Ringel, MD, and Associate Editor Robert Holloway, MD, offer an analysis of the findings. For more discussion, read the Sept. 19 Neurology Today story, “A New Tool for Determining Levels of Consciousness.”]]>Wed, 25 Sep 2013 15:34:09 GMT-05:00http://journals.lww.com/neurotodayonline/pages/videogallery.aspx?videoId=48&autoPlay=truehttp://journals.lww.com/neurotodayonline/pages/videogallery.aspx?videoId=49&autoPlay=true
New England Journal of Medicine, found an elevated risk for dementia even when blood sugar levels were far into the normal range, well below levels associated with diabetes or even prediabetes. In a video interview, Neurology Today Editor-in-chief Steven P. Ringel, MD, and Associate Editor Robert Holloway, MD, discuss the findings — and offer some caveats: among them, this was an association study and the measures compared are cognitive screening every two years and the average of all glucoses drawn over that time — many variables could be influencing these results. And there is some ambiguity — for example, it’s difficult to discriminate reliably among causes of dementia in this study. Still, the study raises many questions about how neurologists could or should be managing diabetes as a comorbidity, and whether clinicians should be thinking of the brain as another organ with the potential for end organ damage. Read the Sept. 19 Neurology Today story, “High Glucose Levels Associated with increased Risk for Dementia.”]]>Wed, 25 Sep 2013 15:41:33 GMT-05:00http://journals.lww.com/neurotodayonline/pages/videogallery.aspx?videoId=49&autoPlay=truehttp://journals.lww.com/neurotodayonline/pages/videogallery.aspx?videoId=50&autoPlay=true
Tue, 01 Oct 2013 09:17:09 GMT-05:00http://journals.lww.com/neurotodayonline/pages/videogallery.aspx?videoId=50&autoPlay=truehttp://journals.lww.com/neurotodayonline/pages/videogallery.aspx?videoId=51&autoPlay=true
In the July 23 edition of Circulation, investigators reported that Octaplex, a four-factor prothrombin complex concentrate (PCC), was faster and safer than fresh frozen plasma; the four-factor PCC was associated with fewer adverse events, faster INR (international normalized ratio) reversal, and less need for red blood cell transfusion.

In a video interview with Neurology Today, Neurology Today Editor-in-Chief Steven P. Ringel, MD, and Associate Editor Robert Holloway Jr., MD, discuss the data in the paper and the pros and cons of accepting the authors’ conclusions in practice. More needs to be studied in terms of the therapy’s cost-effectiveness, the two neurologists agree. But, according to Dr. Holloway, these data provide compelling reasons
why neurologists should check to see whether their pharmacies do have PCC in their formularies. See the full story in the Sept. 19 issue of Neurology Today.

]]>Tue, 01 Oct 2013 09:55:21 GMT-05:00http://journals.lww.com/neurotodayonline/pages/videogallery.aspx?videoId=51&autoPlay=truehttp://journals.lww.com/neurotodayonline/pages/videogallery.aspx?videoId=52&autoPlay=true
Neurology Today.]]>Mon, 04 Nov 2013 11:58:39 GMT-06:00http://journals.lww.com/neurotodayonline/pages/videogallery.aspx?videoId=52&autoPlay=truehttp://journals.lww.com/neurotodayonline/pages/videogallery.aspx?videoId=53&autoPlay=true
Two new developments reported at the 2013
American Neurological Association annual meeting have neuromuscular specialists excited for the first time in a while about potential “breakthroughs” for a disorder that has been difficult to diagnose and treat. In a video interview, Neurology Today Editor-in-chief Steven P. Ringel, MD, and Associate Editor Robert G. Holloway Jr., MD, discuss what’s known about the clinical phenotype of sporadic inclusion body myositis and how it’s currently diagnosed, as well as the two different “camps” in thinking about its underlying mechanism — whether there is an inflammatory or degenerative process. Hear more about the current standards for treatment and their shortcomings, as well as why the findings from the new report — the increase in thigh muscle volume and the suggestion of additional improvements in function — are potential breakthroughs.

For more discussion, read the Nov. 21 Neurology Today reports from the ANA meeting.

]]>Tue, 19 Nov 2013 16:35:18 GMT-06:00http://journals.lww.com/neurotodayonline/pages/videogallery.aspx?videoId=53&autoPlay=truehttp://journals.lww.com/neurotodayonline/pages/videogallery.aspx?videoId=54&autoPlay=true
New England Journal of Medicine, two neuroethicists offer reasons why the standard should or should not be changed.
Now, in an exclusive video interview, Neurology
Today Editor-in-chief Steven P. Ringel, MD, and
Associate Editor Robert G. Holloway Jr., MD, provide insights to these, among other, questions: Is the DDR still relevant? Should patients and their families be allowed the autonomy to opt for donation before death?

If the rule changes, how would that affect laws and medical practice? Watch the video for more discussion about the standards in place for the DDR, concerns about the variability in applying criteria for brain death, and the issue of patient autonomy in the context of shortages of organs for donation. For discussion from other leading neuroethicists and neurointensivists, read the Nov. 7 Neurology Today article, “A Matter of Debate: Is it Time to Revisit the Dead Donor Rule?”

]]>Tue, 19 Nov 2013 16:37:49 GMT-06:00http://journals.lww.com/neurotodayonline/pages/videogallery.aspx?videoId=54&autoPlay=truehttp://journals.lww.com/neurotodayonline/pages/videogallery.aspx?videoId=55&autoPlay=true
Thu, 19 Dec 2013 12:17:29 GMT-06:00http://journals.lww.com/neurotodayonline/pages/videogallery.aspx?videoId=55&autoPlay=truehttp://journals.lww.com/neurotodayonline/pages/videogallery.aspx?videoId=56&autoPlay=true
Neurology Today’s “Best Advances of 2013,” David Gill, MD, an editorial advisory board member, selected a Neurology study that looked at autopsies of subjects with and without symptoms of Alzheimer’s disease (AD) who had varying degrees of AD neuropathologic changes. Among the findings, expression of AD symptoms was affected more by neurofibrillary tangle scores than neuritic plaque burden, and symptomatic patients tended to be older, have a history of recent depression, and have higher Hachinski Ischemic Scores, suggestive of vascular dementia (although cerebrovascular pathology was not associated with symptoms). Editor-in-Chief Steven P. Ringel, MD, and Dr. Gill discuss the unanswered questions raised by these findings, including: Is amyloid imaging a good idea for patients at this point? If amyloid is found in the brain, does that mean the patient will develop Alzheimer’s disease? Are PET scans and spinal taps more or less accurate than clinical acumen? See the full “Best Advances of 2013: Picks from the Neurology Today Editorial Advisory Board” article in our Dec. 19 issue: http://bit.ly/IYORLE.]]>Tue, 31 Dec 2013 12:08:21 GMT-06:00http://journals.lww.com/neurotodayonline/pages/videogallery.aspx?videoId=56&autoPlay=truehttp://journals.lww.com/neurotodayonline/pages/videogallery.aspx?videoId=57&autoPlay=true
Neurology Today’s editorial advisory board, selected a paper in this year’s Brain that examined the vascular components of dementia in autopsy cases for Neurology Today’s “Best Advances of 2013.” All types of dementias were found to have a vascular component, according to the study. In a video interview, Neurology Today Editor-in-Chief Steven P. Ringel, MD, and David Gill, MD, an editorial advisory board member, talk about how these data may affect management of Alzheimer’s patients — or at least the discussion they should elicit in the clinical care setting. See the full “Best Advances of 2013: Picks from the Neurology Today Editorial Advisory Board” article in our Dec. 19 issue: http://bit.ly/IYORLE.]]>Tue, 31 Dec 2013 12:25:27 GMT-06:00http://journals.lww.com/neurotodayonline/pages/videogallery.aspx?videoId=57&autoPlay=truehttp://journals.lww.com/neurotodayonline/pages/videogallery.aspx?videoId=58&autoPlay=true
Neurology Today’s annual “Best Advances” selection, editorial board members Kevin N. Sheth, MD, and James C. Grotta, MD, selected a study from the New England Journal of Medicine that looked at endovascular therapy for ischemic stroke versus tPA alone, and found that endovascular therapy was not superior to tPA for stroke management. Neurology Today Editor-in-Chief Steven P. Ringel, MD, and Associate Editor Robert G. Holloway Jr., MD, MPH, discuss why this study has been a game-changer for the field, but also the limitations which may have affected the findings and require further study. See the full “Best Advances of 2013: Picks from the Neurology Today Editorial Advisory Board” article in our Dec. 19 issue: http://bit.ly/IYORLE.]]>Tue, 31 Dec 2013 13:01:07 GMT-06:00http://journals.lww.com/neurotodayonline/pages/videogallery.aspx?videoId=58&autoPlay=truehttp://journals.lww.com/neurotodayonline/pages/videogallery.aspx?videoId=59&autoPlay=true
Neurology Today’s annual “Best Advances of 2013” issue. The study observed the predictive ability of a seizure advisory system for patients with treatment-resistant epilepsy. Neurology Today Editor-in-Chief Steven P. Ringel, MD, and Associate Editor Robert G. Holloway Jr., MD, MPH, talk about the implications of this proof-of-principle study for patients, caregivers, and clinicians in the future. See the full “Best Advances of 2013: Picks from the Neurology Today Editorial Advisory Board” article in our Dec. 19 issue: http://bit.ly/IYORLE.]]>Tue, 31 Dec 2013 13:12:30 GMT-06:00http://journals.lww.com/neurotodayonline/pages/videogallery.aspx?videoId=59&autoPlay=truehttp://journals.lww.com/neurotodayonline/pages/videogallery.aspx?videoId=60&autoPlay=true
Tue, 31 Dec 2013 13:40:34 GMT-06:00http://journals.lww.com/neurotodayonline/pages/videogallery.aspx?videoId=60&autoPlay=truehttp://journals.lww.com/neurotodayonline/pages/videogallery.aspx?videoId=61&autoPlay=true
Neurology Today Editor-in-chief Steven P. Ringel, MD, at the 2013 American Neurological Association (ANA) annual meeting in New Orleans to discuss his goals for the ANA during his tenure. Dr. Brown said the ANA will “continue the incredible effort to get young people” involved, reach out to colleagues in pharma, and expand their international outreach — in hopes of furthering the ANA’s mission of understanding and treating neurological diseases. Dr. Brown also discussed the looming changes in U.S. health care and research — and how the ANA will respond.]]>Thu, 02 Jan 2014 13:20:18 GMT-06:00http://journals.lww.com/neurotodayonline/pages/videogallery.aspx?videoId=61&autoPlay=truehttp://journals.lww.com/neurotodayonline/pages/videogallery.aspx?videoId=62&autoPlay=true
Thu, 02 Jan 2014 13:34:12 GMT-06:00http://journals.lww.com/neurotodayonline/pages/videogallery.aspx?videoId=62&autoPlay=truehttp://journals.lww.com/neurotodayonline/pages/videogallery.aspx?videoId=63&autoPlay=true
Two separate studies have identified metabolic syndrome and time spent in the intensive care unit (ICU) as independent risk factors for cognitive decline. The first analysis, which used data on 2,975 people, ages 60 and older, from the Centers for Disease Control and Prevention’s National Health and Nutrition Examination Survey, found that those respondents with metabolic syndrome had an odds ratio of 1.40 for cognitive decline, compared to those without metabolic syndrome (p=.034). These data were presented at the American Neurological Association’s annual meeting last October; the full discussion and findings are available here: http://bit.ly/IFc3y9.

The second report, from the Bringing to Light the Risk Factors and Incidence of Neuropsychological Dysfunction in ICU Survivors (BRAIN-ICU) study, found that among 821 adult patients who had experienced episodes of delirium while in the ICU for respiratory failure, cardiogenic or septic shock, although only 6 percent had cognitive deficits at baseline, more than 50 percent developed measurable symptoms of cognitive impairment three and 12 months after discharge. The findings were reported in the Oct. 3 issue of the New England Journal of Medicine, and in a Nov. 7 article in Neurology Today: http://bit.ly/IKCJ10.

Here, in a video interview, Neurology Today Editor-in-chief Steven P. Ringel, MD, and Associate Editor Robert G. Holloway Jr., MD, MPH, provide insights into these two analyses, and discuss their potential clinical implications for treating patients in the ICU setting and after discharge.